Delivery Order SPE2DR25D9239-SPE2DR26FFCT5
Award Date 4/21/26
Potential Completion Date 5/12/26
Potential Value $20K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 24, 2026, for 3,750 units of Oncaspar 5 ml vials, with a ceiling value of $20,358.98. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract vehicle supporting recurring pharmaceutical supply for Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group Inc. is a...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on March 3, 2026, for 3,750 units of Oncaspar 5 mL vials with a ceiling value of $40,717.98. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), the Defense Logistics Agency's indefinite delivery contract vehicle for pharmaceutical products and medical consumables supporting Department of Defense healthcare operations globally. DMS Pharmaceutical Group is a...
- The Defense Logistics Agency issued a $40,717.98 delivery order to DMS Pharmaceutical Group Inc. on April 13, 2026, for 3,750 units of Oncaspar 5 mL vials, with ultimate completion on May 4, 2026. The order is issued under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a single-award indefinite delivery contract with a $499.999 billion ceiling through December 31, 2036. DMS Pharmaceutical Group Inc. is a woman-owned small business...
- <p>The Defense Logistics Agency issued a $40,717.98 delivery order to DMS Pharmaceutical Group Inc. on March 9, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for 3,750 units of Oncaspar 5 ML vials.</p> <p>DMS Pharmaceutical Group Inc. is a woman-owned small business. The order is firm fixed price with an ultimate completion date of March 30, 2026. Place of performance is Park Ridge, IL.</p>
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on April 15, 2026, for oncology pharmaceutical supply (Oncaspar, 3,750 units, 5 milliliter vials) with a ceiling value of $20,358.98. The order is issued under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a Defense Logistics Agency indefinite delivery contract that authorizes firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 3,750 units of Oncaspar 5 ml vials valued at $40,717.98. The award, issued on January 29, 2026, with an ultimate completion date of February 20, 2026, carries a firm fixed-price structure with no small business set-aside designation, indicating the contractor competed in open federal procurement. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $40,717.98 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on January 22, 2026. The delivery order covers 3,750 units of Oncaspar 5 milliliter vials, an oncology pharmaceutical product, with a firm fixed-price structure and an ultimate completion date of February 12, 2026. This award was issued without a set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency issued a $3,863.68 delivery order to DMS Pharmaceutical Group Inc. on April 10, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) for pharmaceutical products. PPV-G GEN V is a $30.3 billion Defense Logistics Agency acquisition strategy establishing multiple regional prime vendor contractors to supply branded and generic prescription drugs, over-the-counter medications, biologics, vaccines, specialty pharmaceuticals, and medical...
- The Defense Logistics Agency issued a $12,054 delivery order to DMS Pharmaceutical Group Inc. on April 17, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V). PPV-G GEN V is a Defense Logistics Agency indefinite delivery contract authorizing firm fixed-price delivery orders for pharmaceutical products and medical consumables supporting Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical is a woman-owned small business and the sole...
- The Defense Logistics Agency issued a $1,529.03 delivery order to DMS Pharmaceutical Group Inc. on April 8, 2026, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract for pharmaceutical products and medical consumables. PPV-G GEN V is the Defense Logistics Agency's $30.3 billion acquisition strategy establishing multiple regional prime vendor contractors authorized to supply branded and generic prescription medications, over-the-counter...